76756 Federal Register / Vol. 75, No. 236 / Thursday, December 9, 2010 / Notices 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30897 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated July 19, 2010, and 

published in the Federal Register on 

July 28, 2010, (75 FR 44285), Johnson 

Matthey Pharmaceutical Materials, Inc., 

Pharmaceuticals Service, 25 Patton 

Road, Devens, Massachusetts 01434, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Remifentanil (9739) ...................... II 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Pharmaceutical 

Materials, Inc. to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Pharmaceutical Materials, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30904 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 16, 2010, and 

published in the Federal Register on 

March 24, 2010, (75 FR 14189), Norac 

Inc., 405 S. Motor Avenue, P.O. Box 

577, Azusa, California 91702–3232, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Tetrahydrocannabinols (7370) ..... I 

Methamphetamine (1105) ............ II 

Nabilone (7379) ............................ II 

With regard to Gamma 

Hydroxybutyric Acid (2010), 

Tetrahydrocannabinols (7370), and 

Methamphetamine (1105) only, the 

company manufactures these controlled 

substances in bulk solely for domestic 

distribution within the United States to 

customers engaged in dosage-form 

manufacturing. 

With regard to Nabilone (7379) only, 

the company presently manufactures a 

small amount of this controlled 

substance in bulk solely to conduct 

manufacturing process development 

internally within the company. It is the 

company’s intention that, when the 

manufacturing process is refined to the 

point that its Nabilone bulk product is 

available for commercial use, the 

company will export the controlled 

substance in bulk solely to customers 

engaged in dosage-form manufacturing 

outside the United States. The company 

is aware of the requirement to obtain a 

DEA registration as an exporter to 

conduct this activity. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Norac, Inc. to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Norac, 

Inc. to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30903 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated July 23, 2010, and 

published in the Federal Register on 

August 4, 2010, (75 FR 47029), Johnson 

Matthey Pharma Services, 70 Flagship 

Drive, North Andover, Massachusetts 

01845, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 75, No. 236 / Thursday, December 9, 2010 / Notices 76757 

determined that the registration of 

Johnson Matthey Pharma Services to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Johnson Matthey Pharma 

Services to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30899 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL SCIENCE FOUNDATION 

National Science Board; Sunshine Act 

Meetings; Notice 

The National Science Board’s 

Subcommittee on Facilities, pursuant to 

NSF regulations (45 CFR Part 614), the 

National Science Foundation Act, as 

amended (42 U.S.C. 1862n–5), and the 

Government in the Sunshine Act (5 

U.S.C. 552b), hereby gives notice in 

regard to the scheduling of a meeting for 

the transaction of National Science 

Board business and other matters 

specified, as follows: 

DATE: December 15, 2010. 

TIME AND SUBJECT MATTER OPEN: 11 a.m. 

to 12:30 p.m. 

• NSF Principles & Portfolio Review 

• Future Budgetary Issues FY 2012 

and beyond 

STATUS: Closed. 

LOCATION: The closed session of this 

teleconference will be held at the 

National Science Foundation, 4201 

Wilson Blvd., Arlington, VA 22230. 

UPDATES AND POINT OF CONTACT: Please 

refer to the National Science Board Web 

site http://www.nsf.gov/nsb for 

additional information and schedule 

updates (time, place, subject matter or 

status of meeting) may be found at 

http://www.nsf.gov/nsb/notices/. Point 

of contact for this meeting is: Jennie 

Moehlmann, National Science Board 

Office, 4201 Wilson Blvd., Arlington, 

VA 22230. Telephone: (703) 292–7000. 

Daniel A. Lauretano, 

Counsel to the National Science Board. 

[FR Doc. 2010–31067 Filed 12–7–10; 4:15 pm] 

BILLING CODE 7555–01–P 

NUCLEAR REGULATORY 

COMMISSION 

[Docket Nos. 50–498, 50–499; NRC–2010– 

0375] 

STP Nuclear Operating Company; 

Notice of Receipt and Availability of 

Application for Renewal of South 

Texas Project, Units 1 and 2; Facility 

Operating License Nos. NPF–76 and 

NPF–80 for an Additional 20-Year 

Period 

The U.S. Nuclear Regulatory 

Commission (NRC or Commission) has 

received an application, dated October 

25, 2010, from STP Nuclear Operating 

Company, filed pursuant to Section 103 

of the Atomic Energy Act of 1954, as 

amended, and Title 10 of the Code of 

Federal Regulations part 54 (10 CFR 

part 54), to renew the operating licenses 

for the South Texas Project (STP), Units 

1 and 2. Renewal of the licenses would 

authorize the applicant to operate each 

facility for an additional 20-year period 

beyond the period specified in the 

respective current operating licenses. 

The current operating license for STP 

Unit 1 (NPF–76) expires on August 20, 

2027. STP Unit 1 is a pressurized water 

reactor designed by Westinghouse. The 

current operating license for STP Unit 2 

expires on December 15, 2028. STP Unit 

2 is a pressurized water reactor designed 

by Westinghouse. Both units are located 

12 miles south southwest of Bay City, 

TX. The acceptability of the tendered 

application for docketing, and other 

matters including an opportunity to 

request a hearing, will be the subject of 

subsequent Federal Register notices. 

Copies of the application are available 

to the public at the Commission’s Public 

Document Room (PDR), located at One 

White Flint North, 11555 Rockville 

Pike, Rockville, Maryland 20852 or 

through the Internet from the NRC’s 

Agencywide Documents Access and 

Management System (ADAMS) Public 

Electronic Reading Room under 

Accession Number ML103010256. The 

ADAMS Public Electronic Reading 

Room is accessible from the NRC Web 

site at http://www.nrc.gov/reading-rm/ 

adams.html. In addition, the application 

is available at http://www.nrc.gov/ 

reactors/operating/licensing/renewal/ 

applications.html. Persons who do not 

have access to the Internet or who 

encounter problems in accessing the 

documents located in ADAMS should 

contact the NRC’s PDR reference staff at 

1–800–397–4209, extension 4737, or by 

e-mail to pdr@nrc.gov. 

A copy of the license renewal 

application for the STP, Units 1 and 2, 

is also available to local residents near 

the site at the Bay City Public Library, 

1100 7th Street, Bay City, TX 77414. 

Dated at Rockville, Maryland, this 23rd day 

of November, 2010. 

For the Nuclear Regulatory Commission. 

A. Louise Lund, 

Acting Deputy Director, Division of License 

Renewal, Office of Nuclear Reactor 

Regulation. 

[FR Doc. 2010–30956 Filed 12–8–10; 8:45 am] 

BILLING CODE 7590–01–P 

NUCLEAR REGULATORY 

COMMISSION 

Licensing Support System Advisory 

Review Panel 

AGENCY: U.S. Nuclear Regulatory 

Commission. 

ACTION: Notice of renewal of the Charter 

of the Licensing Support Network 

Advisory Review Panel (LSNARP). 

SUMMARY: The Licensing Support 

System Advisory Review Panel was 

established by the U.S. Nuclear 

Regulatory Commission as a Federal 

Advisory Committee in 1989. Its 

purpose was to provide advice on the 

fundamental issues of design and 

development of an electronic 

information management system to be 

used to store and retrieve documents 

relating to the licensing of a geologic 

repository for the disposal of high-level 

radioactive waste, and on the operation 

and maintenance of the system. This 

electronic information management 

system was known as the Licensing 

Support System (LSS). In November, 

1998 the Commission approved 

amendments to 10 CFR part 2 that 

renamed the Licensing Support System 

Advisory Review Panel as the Licensing 

Support Network Advisory Review 

Panel. The Licensing Support Network 

(LSN) in use since 2004 and now 

contains over 4 million documents 

associated the proposed high-level 

waste facility. 

Membership on the Panel will 

continue to be drawn from those 

interests that will be affected by the use 

of the LSN, including the Department of 

Energy, the NRC, the State of Nevada, 

the National Congress of American 

Indians, affected units of local 

governments in Nevada, the Nevada 

Nuclear Waste Task Force, and a 


erowe on DSK5CLS3C1PROD with NOTICES